Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma
Proliferating cells express the pyruvate kinase isoenzyme type M2 (M2-PK). This enzyme exists as an active tetramer and an inactive dimer. The dimeric form is predominantly found in tumor cells and is therefore termed Tumor M2-PK (TuM2-PK). TuM2-PK molecules are released into the peripheral blood an...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
14 June 2005
|
| In: |
International journal of cancer
Year: 2005, Volume: 117, Issue: 5, Pages: 825-830 |
| ISSN: | 1097-0215 |
| DOI: | https://doi.org/10.1002/ijc.21073 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/https://doi.org/10.1002/ijc.21073 Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.21073 
|
| Author Notes: | Selma Ugurel, Nellie Bell, Antje Sucker, Anette Zimpfer, Werner Rittgen and Dirk Schadendorf |
| Summary: | Proliferating cells express the pyruvate kinase isoenzyme type M2 (M2-PK). This enzyme exists as an active tetramer and an inactive dimer. The dimeric form is predominantly found in tumor cells and is therefore termed Tumor M2-PK (TuM2-PK). TuM2-PK molecules are released into the peripheral blood and may hereby function as a marker of tumor load in cancer patients. Our study was aimed to investigate TuM2-PK as a potential plasma marker in melanoma patients compared to the well-established serum marker S100β. We measured the concentration of TuM2-PK in plasma and S100β in corresponding serum samples from 300 melanoma patients and 53 healthy controls using a sandwich ELISA and an immunoluminometric assay, respectively. Plasma concentrations of TuM2-PK were significantly increased in melanoma patients compared to healthy controls (9.30 U/ml vs. 7.20 U/ml; p = 0.0036) and correlated with tumor load (p < 0.0005) and disease stage (p < 0.0005). Patients with elevated plasma TuM2-PK (cut-off = 15 U/ml) presented a reduced overall (p < 0.000005) and progression-free (p = 0.023) survival. Multivariate analysis revealed plasma TuM2-PK and serum S100β as independent predictors of overall survival in metastasized patients. Neither plasma TuM2-PK nor serum S100β showed prognostic relevance for tumor-free patients. Although the sensitivity and specificity to predict disease progression or death was higher for serum S100β compared to plasma TuM2-PK, the combination of both markers improved the estimation of prognosis compared to that of serum S100β alone. |
|---|---|
| Item Description: | Gesehen am 22.01.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1097-0215 |
| DOI: | https://doi.org/10.1002/ijc.21073 |